ImmuCell Corp Reports Material Agreements and Officer Changes

TL;DR

ImmuCell Corp inked new deals, ditched old ones, and shuffled execs.

AI Summary

On December 6, 2024, ImmuCell Corporation entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. The company also reported the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for these officers.

Why It Matters

This filing indicates significant corporate actions, including new agreements and changes in leadership, which could impact the company's strategic direction and operational stability.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and changes in officers/directors, which can introduce uncertainty and potential shifts in strategy.

Key Players & Entities

• ImmuCell Corporation (company) — Registrant
• December 6, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ
• $100,000 — ll be entitled to a one-time payment of $100,000, less an amount equal to the wages earn

Filing Documents

• ea0224119-8k_immucell.htm (8-K) — 28KB
• ea022411901ex10-1_immucell.htm (EX-10.1) — 32KB
• 0001213900-24-106933.txt ( ) — 237KB
• iccc-20241206.xsd (EX-101.SCH) — 3KB
• iccc-20241206_lab.xml (EX-101.LAB) — 33KB
• iccc-20241206_pre.xml (EX-101.PRE) — 22KB
• ea0224119-8k_immucell_htm.xml (XML) — 3KB

01 – Entry into a Material Definitive Agreement

Item 1.01 – Entry into a Material Definitive Agreement The information set forth in Item 5.02 below is hereby incorporated by reference into this Item 1.01.

02 – Termination of a Material Definitive Agreement

Item 1.02 – Termination of a Material Definitive Agreement The information set forth in Item 5.02 below is hereby incorporated by reference into this Item 1.02.

02 – Departure of Directors or Certain Officers; Election

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 6, 2024, ImmuCell Corporation (the "Company") and Elizabeth L. Williams, a Named Executive Officer of the Company who has served as the Company's Vice President of Manufacturing Operations since April 2016, entered into an Employment and Separation Agreement (the "Employment and Separation Agreement"), pursuant to which Ms. Williams will serve in a part-time role with the Company until her retirement on July 1, 2025. Pursuant to the Employment and Separation Agreement, Ms. Williams will continue to be employed by the Company on a part-time basis through July 1, 2025 in order to perform and transition tasks related to her previous role with the Company. The Employment and Separation Agreement supersedes and replaces all prior agreements concerning Ms. Williams's employment with and compensation from the Company, including but not limited to that certain Fifth Amended and Restated Incentive Compensation Agreement, dated as of March 27, 2024, by and between Ms. Williams and the Company. In the event Ms. Williams continues to work for the Company on a part-time basis and otherwise complies with the terms of the Employment and Separation Agreement through June 30, 2025, she will be entitled to a one-time payment of $100,000, less an amount equal to the wages earned by Ms. Williams during that time. The forgoing description of the Employment and Separation Agreement is qualified in all respects by reference to the full text of the Employment and Separation Agreement, attached to this Current Report as Exhibit 10.1 and incorporated into this Item 5.02 by reference.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 10.1 Employment and Separation Agreement between the Company and Elizabeth L. Williams dated as of December 6, 2024 104 Cover Page Interactive Data File 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: December 9, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President and Chief Executive Officer 2 EXHIBIT INDEX Exhibit No. Description 10.1 Employment and Separation Agreement between the Company and Elizabeth L. Williams dated as of December 6, 2024 104 Cover Page Interactive Data File 3

View Full Filing

View this 8-K filing on SEC EDGAR